daily oral glp-1 receptor agonist orforglipron for adults with obesity New pill reduces weight in trial Learn about Orforglipron a weight

Animal studies demonstrate retatrutides ability to delay gastric emptying, reduce food intake, and promote weight loss, with superior efficacy compared to other incretin-based therapies

Randomised controlled trial of bariatric surgery versus a community weight loss programme for the sustained treatment of idiopathic intracranial hypertension: the idiopathic intracranial hypertension weight trial (IIH: WT) protocol

( Epub 20211021 )

Comparative Efficacy and Safety of GLP-1 Receptor Agonists for Weight Reduction: A Model-Based Meta-Analysis of Placebo-Controlled Trials

It also has another obesity drug moving to late-stage clinical trials, eloralintide, with promising data that further builds on [Lillys] leadership position in the obesity and Type 2 diabetes market, according to a Nov